Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In vitro combined effect of co-amoxiclav concentrations achievable in serum after a 2000/125 mg oral dose, and polymorphonuclear neutrophils against strains of Streptococcus pneumoniae exhibiting decreased susceptibility to amoxicillin.
Amores R, Alou L, Giménez MJ, Sevillano D, Gómez-Lus ML, Aguilar L, Prieto J. Amores R, et al. Among authors: alou l. Int J Antimicrob Agents. 2004 Jul;24(1):79-82. doi: 10.1016/j.ijantimicag.2004.01.016. Int J Antimicrob Agents. 2004. PMID: 15225866
Bactericidal activity of moxifloxacin against multidrug-resistant Streptoccocus pneumoniae at clinically achievable serum and epithelial lining fluid concentrations compared with three other antimicrobials.
Cafini F, Alou L, Sevillano D, Valero E, Prieto J; Spanish Pneumococcal Infection Study Network (G03/103). Cafini F, et al. Among authors: alou l. Int J Antimicrob Agents. 2004 Oct;24(4):334-8. doi: 10.1016/j.ijantimicag.2004.04.015. Int J Antimicrob Agents. 2004. PMID: 15380257
Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation.
Sevillano D, Calvo A, Giménez MJ, Alou L, Aguilar L, Valero E, Carcas A, Prieto J. Sevillano D, et al. Among authors: alou l. J Antimicrob Chemother. 2004 Dec;54(6):1148-51. doi: 10.1093/jac/dkh463. Epub 2004 Oct 15. J Antimicrob Chemother. 2004. PMID: 15489246
Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae after administration of a single oral dose of pharmacokinetically enhanced 2000/125 mg co-amoxiclav to healthy volunteers.
Alou L, Aguilar L, Sevillano D, Giménez MJ, Laguna B, Echeverría O, Carcas A, Lubomirov R, Casal J, Prieto J. Alou L, et al. J Antimicrob Chemother. 2005 May;55(5):742-7. doi: 10.1093/jac/dki071. Epub 2005 Mar 10. J Antimicrob Chemother. 2005. PMID: 15761068 Clinical Trial.
Urine bactericidal activity against resistant Escherichia coli in an in vitro pharmacodynamic model simulating urine concentrations obtained after 2000/125 mg sustained-release co-amoxiclav and 400 mg norfloxacin administration.
Alou L, Aguilar L, Sevillano D, Giménez MJ, Cafini F, Valero E, Relaño MT, Prieto J. Alou L, et al. J Antimicrob Chemother. 2006 Apr;57(4):714-9. doi: 10.1093/jac/dkl041. Epub 2006 Feb 21. J Antimicrob Chemother. 2006. PMID: 16492718
94 results